Navigation Links
Biogenerics Will Save Billions, Says Hospira CEO
Date:9/6/2007

- GPhA Keynote Emphasizes Generic Industry Readiness and Questions Fiscal

and Social Responsibility of Delaying Biogenerics -

WASHINGTON, Sept. 6 /PRNewswire-FirstCall/ -- Expensive biologic medicines are arriving at a critical crossroads as decades-old patents expire, and generic companies stand ready to add biogenerics to the industry's portfolio. Now is the time to pass legislation enabling the U.S. Food and Drug Administration (FDA) to create an abbreviated regulatory pathway for safe, pure and effective biogenerics, Hospira CEO and Chairman Christopher Begley said today in a keynote address at the Generic Pharmaceutical Association's (GPhA) Annual Policy Conference.

Biologic medicines, unlike traditional pharmaceuticals, are manufactured from complex living cells. They provide some of the most effective treatment options for serious diseases like cancer and diabetes, but are very expensive. A biologic to treat colon cancer, for example, costs $100,000 a year.(1) Some biologics can cost up to $200,000 annually.(2)

"When life-saving drugs are not affordable -- regardless of their safety and efficacy -- they are irrelevant," Begley said.

Representing about 250 of the more than 10,000 drugs approved by the FDA, branded biologics claim a disproportionate share of the nation's healthcare spending: (3,4)

-- In 2006, sales of biologics rose to the $30 to $40 billion range,

accounting for about 15 percent of all U.S. drug sales. (2,5)

-- In 2006, biologics cost Medicare Part B alone more than

$5 billion.(2)

-- Corporations have testified before Congress that they can't continue

to sustain the growing contribution of biologics to their employee

healthcare costs.(6)

Taking the stage in Washington, in front of approximately 200 attendees, Begley said when the technology exists today to create effective, safe and less expensive biogenerics, the continual lack of a
'/>"/>

SOURCE Hospira, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/17/2013)... International, Inc. (NASDAQ: YONG ) ("Yongye" or ... crop nutrient products in the People,s Republic ... 16, 2013, the special committee (the "Special Committee") of ... provided a letter (the "Letter") issued by Abax Global ... to Full Alliance International Limited ("Full Alliance"). The Letter, ...
(Date:5/17/2013)... The paradigm of ‘one drug, one target’ ... help predict the adverse and therapeutic effects of a ... Computational Biology at the Genomics Laboratory, Covance, will discuss ... genomics when used as part of the QC process. ... sets to identify key clinical targets even in complex ...
(Date:5/17/2013)... Tooth decay is an epidemic in American children with ... The World Health Organization says that worldwide, 60–90% ... What are the long-term effects of this transmissible infection? ... the oral bacterial imbalance and serious systemic issues like heart ... is also 100% preventable? Answer: there has been no way ...
(Date:5/16/2013)... May 16, 2013 In late 2012, Dr. ... speak to doctors in China about Appearance Medicine . ... this was her first trip to lecture in China, and ... Guangzhou and Fuzhou, home to 12 and 7 million people ... very high at this point in time. As Dr. Hart ...
Breaking Biology Technology:Yongye International Provides Update on Status of Proposed Go Private Offer 2Yongye International Provides Update on Status of Proposed Go Private Offer 3Yongye International Provides Update on Status of Proposed Go Private Offer 4Seeing the Future: How a Revolutionary New Bacterial Screening Device Can Predict a Patient’s Future for Tooth Decay 2Seeing the Future: How a Revolutionary New Bacterial Screening Device Can Predict a Patient’s Future for Tooth Decay 3
... Biosciences, Inc. announced today that David J. Mazzo, Ph.D., ... the 27th Annual J.P. Morgan Healthcare Conference in San ... Pacific Time (2:30pm Eastern Time). Dr. Mazzo,s presentation ... in development, the REG1 System, its pipeline and enterprise-level ...
... Accumetrics, Inc. has appointed Andrew Chisholm to the position ... right mix of energy and expertise to Accumetrics. ... in terms of our market penetration," says Timothy I. ... the medical diagnostics industry and his relationships with distributors ...
... Company,s commitment to innovation in drug-eluting stent technologyNATICK, ... BSX ) today announced that it ... drug-eluting stent technology company located in Galway, Ireland. ... has developed a novel technology for coating drug-eluting ...
Cached Biology Technology:Andrew Chisholm Appointed Vice President, Sales and Corporate Accounts at Accumetrics 2Boston Scientific Acquires Labcoat Limited 2Boston Scientific Acquires Labcoat Limited 3Boston Scientific Acquires Labcoat Limited 4
(Date:5/16/2013)... Injectable nanoparticles developed at MIT may someday eliminate ... to constantly monitor their blood-sugar levels and inject ... to sense glucose levels in the body and ... thereby replacing the function of pancreatic islet cells, ... diabetes. Ultimately, this type of system could ensure ...
(Date:5/16/2013)... May 16, 2013 Integrated Biometrics patented ... a custom thin film transistor camera introduces Sherlock, ... roll image in the smallest and lightest form ... Appendix F Mobile ID FAP 45, Certified scanner ... in size and weight when compared to optical ...
(Date:5/16/2013)... The use of genome-wide analysis (GWA), where the entirety ... the genomic mutations or variants which can cause health ... However, it can also pose major ethical problems ... Society of Human Genetics (ESHG) published on line today ... Human Genetics ., Many services based on whole genome ...
Breaking Biology News(10 mins):Nanotechnology could help fight diabetes 2Nanotechnology could help fight diabetes 3European Society of Human Genetics urges caution over use of new genetic sequencing techniques 2
... RNA nano-scaffold that remains unusually stable in the body, ... another barrier to the development of therapeutic RNA nanotechnology. ... Endowed Chair and professor of biomedical engineering, and his ... report the construction of a thermodynamically stable RNA nanoparticle ...
... MINNETONKA, Minn., Sept. 12, 2011 MedNet Solutions, a ... study management systems, is pleased to announce the official ... Designed specifically to help Clinical Research Organizations (CROs) improve ... and win more business, the program provides CROs with ...
... 2011A study presented today by Universit Laval researchers at the ... City revealed that the risk of insomnia is 67% higher ... is an insomniac. The research team, directed by ... came to these conclusions following a study involving 3,485 people. ...
Cached Biology News:Team finds stable RNA nano-scaffold within virus core 2MedNet Solutions Launches the iMedNet CRO Partner Program 2
... reagent is formulated specifically for Alkaline Phosphatase ... levels of activity for both the enzyme ... final dilution. This product has been ... the customer a longer shelf life, resistance ...
... a valuable tool for removing SDS detergent ... SDS in biological samples imparts a negative ... inhibits enzymatic activity during digestion, and suppresses ... in mass spectrometry analyses. We recommend ...
Cells are grown in triple flasks, roller bottles, or NUNC Factory. Viability and growth curves are generated from a parallel representative culture....
... cost effective cell culture services for the ... Quality at a reasonable price is our ... or commercial product, we strive toward customer ... roller bottles, hollow fiber, and bioreactor technologies, ...
Biology Products: